Emergent BioSolutions Inc/ US29089Q1058 /
2024-04-17 9:59:55 PM | Chg. -0.03 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
1.91USD | -1.55% | 15,416 Turnover: 29,456.02 |
-Bid Size: - | -Ask Size: - | 99.19 mill.USD | - | - |
Assets
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Property and Equipment | 376.4480 | 407.2100 | 510.2000 | 542.3000 | 644.1000 | ||||||
Intangible Assets | 33.8650 | 119.5970 | 761.6000 | 712.9000 | 663.1000 | ||||||
Long-Term Investments | - | - | - | - | - | ||||||
Fixed Assets | 459.8930 | 584.8170 | 1,608.6000 | 1,641.1000 | 1,687.3000 | ||||||
Inventories | 74.0020 | 142.8120 | 205.8000 | 222.5000 | 307 | ||||||
Accounts Receivable | 138.4780 | 143.6530 | 262.5000 | 270.7000 | 230.9000 | ||||||
Cash and Cash Equivalents | 271.5130 | 178.2920 | 112.2000 | 167.8000 | 621.3000 | ||||||
Current Assets | 510.2180 | 485.3890 | 620.8000 | 686.2000 | 1,195.9000 | ||||||
Total Assets | 970.1110 | 1,070.2060 | 2,229.4000 | 2,327.3000 | 2,883.2000 |
Liabilities
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Accounts Payable | 34.6490 | 41.7510 | 80.7000 | 94.8000 | 136.1000 | ||||||
Long-term debt | 248.0940 | 13.4570 | 784.5000 | 798.4000 | 841 | ||||||
Liabilities to Banks | - | - | - | - | - | ||||||
Provisions | - | - | 72 | 63.9000 | 53.2000 | ||||||
Liabilities | 373.9060 | 157.8610 | 1,218.5000 | 1,238.8000 | 1,436.2000 | ||||||
Share Capital | - | - | - | - | - | ||||||
Total Equity | 596.2050 | 912.3450 | 1,010.9000 | 1,088.5000 | 1,447 | ||||||
Minority Interests | - | - | - | - | - | ||||||
Total liabilities equity | 970.1110 | 1,070.2060 | 2,229.4000 | 2,327.3000 | 2,883.2000 |
Income Statement
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 488.7820 | 560.8730 | 782.4000 | 1,106 | 1,555.4000 | ||||||
Depreciation (total) | - | - | 25 | 58.7000 | 59.8000 | ||||||
Operating Result | 105.5220 | 124.2850 | 89.8000 | 114.1000 | 433.8000 | ||||||
Interest Income | -6.5640 | -4.8370 | -9.9000 | -38.4000 | -31.3000 | ||||||
Income Before Taxes | 99.2210 | 118.6330 | 81.5000 | 77.4000 | 407.2000 | ||||||
Income Taxes | 36.6970 | 36.0390 | 18.8000 | 22.9000 | 102.1000 | ||||||
Minority Interests Profit | - | - | - | - | - | ||||||
Net Income | 51.7760 | 82.5940 | 62.7000 | 54.5000 | 305.1000 |
Per Share
Cash Flow
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | 53.4870 | 208.1390 | 41.8000 | 188 | 536 | ||||||
Cash Flow from Investing Activities | -76.2570 | -249.9320 | -897.2000 | -96.9000 | -151 | ||||||
Cash Flow from Financing | -18.6410 | -51.4010 | 788.7000 | -35.9000 | 69.5000 | ||||||
Decrease / Increase in Cash | -41.2820 | -93.2210 | -66.9000 | 55.6000 | 453.5000 | ||||||
Employees | 1,098 | 1,256 | 1,705 | 1,834 | 2,200 |